Emergent BioSolutions Inc EBS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EBS is a good fit for your portfolio.
News
-
Update: Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
-
Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
-
Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 Million
-
Emergent BioSolutions Continues Driving Progress Against the Opioid Epidemic & Recognizes National Naloxone Awareness Day
-
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024
-
Emergent BioSolutions Reports First Quarter 2024 Financial Results
-
Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position
-
Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone
Trading Information
- Previous Close Price
- $7.54
- Day Range
- $7.42–7.97
- 52-Week Range
- $1.42–8.29
- Bid/Ask
- $7.74 / $7.95
- Market Cap
- $415.55 Mil
- Volume/Avg
- 1.6 Mil / 4.9 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.34
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN® and other commercial products.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 1,600
Comparables
Valuation
|
Metric
|
EBS
|
MRK
|
GILD
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 57.99 | 16.52 |
Price/Book Value | 0.60 | 7.90 | 4.73 |
Price/Sales | 0.34 | 5.22 | 3.04 |
Price/Cash Flow | 8.46 | 18.35 | 7.81 |
Price/Earnings
EBS
MRK
GILD
Financial Strength
|
Metric
|
EBS
|
MRK
|
GILD
|
|---|---|---|---|
Quick Ratio | 0.50 | 0.68 | 0.72 |
Current Ratio | 1.08 | 1.25 | 1.08 |
Interest Coverage | −4.92 | 3.97 | 2.11 |
Quick Ratio
EBS
MRK
GILD
Profitability
|
Metric
|
EBS
|
MRK
|
GILD
|
|---|---|---|---|
Return on Assets (Normalized) | −6.85% | 5.22% | 8.33% |
Return on Equity (Normalized) | −17.48% | 13.56% | 24.25% |
Return on Invested Capital (Normalized) | −3.92% | 8.29% | 12.71% |
Return on Assets
EBS
MRK
GILD
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Zoetis Inc Class A
ZTS
| Sdsscsnhh | Vmjl | $80.1 Bil | |||
| Merck KGaA ADR
MKKGY
| Rplqnthkx | Vwfjggs | $71.6 Bil | |||
| Haleon PLC ADR
HLN
| Skvwyzzjp | Nrlm | $37.5 Bil | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| Xdchbjcqt | Qbj | $18.9 Bil | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Mkpdhzx | Lmhq | $12.9 Bil | |||
| Viatris Inc
VTRS
| Gyqdhmvh | Hsty | $12.4 Bil | |||
| Catalent Inc
CTLT
| Cdwyrcqd | Mdbwzs | $10.2 Bil | |||
| Perrigo Co PLC
PRGO
| Dvhtsptn | Zcyq | $3.6 Bil | |||
| Prestige Consumer Healthcare Inc
PBH
| Flmvrwdg | Qchrf | $3.4 Bil | |||
| Curaleaf Holdings Inc
CURLF
| Ncwtmdgn | Pqm | $2.9 Bil |